Press releases
- Amneal to Report Second Quarter 2024 Results on August 9, 2024
- Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
- Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
- Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
- Amneal Releases 2023 Environmental, Social and Governance Report
- Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
- Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
- Amneal to Participate at Upcoming Investor Conference
- Amneal Reports First Quarter 2024 Financial Results
- Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
More ▼
Key statistics
As of last trade Amneal Pharmaceuticals Inc (2DT:DEU) traded at 6.90, -10.97% below its 52-week high of 7.75, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.70 |
---|---|
High | 6.90 |
Low | 6.50 |
Bid | 6.75 |
Offer | 6.95 |
Previous close | 6.65 |
Average volume | 184.90 |
---|---|
Shares outstanding | 308.65m |
Free float | 120.40m |
P/E (TTM) | -- |
Market cap | 2.29bn USD |
EPS (TTM) | -0.5642 USD |
Data delayed at least 15 minutes, as of Jul 22 2024.
More ▼